{
    "clinical_study": {
        "@rank": "3185", 
        "arm_group": [
            {
                "arm_group_label": "bismuth subsalicylate (Pepto-Bismol\u00ae) + DMF", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive dimethyl fumarate (DMF) and bismuth subsalicylate (Pepto-Bismol\u00ae)."
            }, 
            {
                "arm_group_label": "Placebo + DMF", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive dimethyl fumarate (DMF) and placebo."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the study is to determine the effect of bismuth subsalicylate\n      (Pepto-Bismol\u00ae) 524 mg versus placebo on gastrointestinal (GI)-related events reported in\n      healthy volunteers receiving TECFIDERA\u2122 (dimethyl fumarate [DMF]; also known as BG00012)\n      twice daily (BID) The secondary objectives of this study in this study population are: To\n      characterize the effect of bismuth subsalicylate (Pepto-Bismol\u00ae) 524 mg versus placebo on\n      the frequency, severity, and duration of GI-related events and to evaluate GI-related events\n      that lead to discontinuation of DMF."
        }, 
        "brief_title": "PeptoBismol\u00ae Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera\u00ae] Twice Daily", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Must be in good health as determined by the Principal Investigator (PI) based on\n             medical history and Screening evaluations (clinical laboratory evaluations, 12-lead\n             electrocardiogram (ECG), and vital signs; see below for specific exclusion criteria).\n\n          -  Must have a body mass index (BMI) of 18.0 to 34.0 kg/m2, inclusive.\n\n          -  Subjects of reproductive potential (including males) must practice effective\n             contraception during the study and be willing and able to continue contraception for\n             90 days after their last dose of study drug.\n\n          -  Male subjects must agree to not donate sperm for 90 days after their last dose of\n             study drug.\n\n          -  Must be na\u00efve to dimethyl fumarate (DMF) or fumaric acid esters.\n\n        Key Exclusion Criteria:\n\n          -  History of or positive results at the Screening visit for HIV.\n\n          -  History of or positive results at the Screening visit for hepatitis C virus antibody\n             or hepatitis B virus (defined as positive for hepatitis B surface antigen [HBsAg] or\n             hepatitis B core antibody [HBcAb]).\n\n          -  History of clinically significant gastrointestinal (GI) disease as determined by the\n             PI (including Crohn's disease, peptic ulcer disease, ulcerative colitis, or confirmed\n             diagnosis of irritable bowel syndrome) or active GI disease with ongoing symptoms.\n\n          -  History of severe allergic or anaphylactic reactions, considered clinically relevant\n             by the PI.\n\n          -  Known allergy to Pepto-Bismol\u00ae, salicylates, or non-steroidal anti-inflammatory\n             drugs, considered clinically relevant by the PI.\n\n          -  Female subjects who are pregnant based on results of the serum pregnancy test at\n             Screening or currently breastfeeding.\n\n          -  Current enrollment in any other study treatment or disease study.\n\n          -  Receipt of any investigational drug within 5 half-lives or 30 days, whichever is\n             longer, prior to study entry.\n\n          -  History of alcohol abuse or substance abuse (as determined by the PI) within the\n             previous 5 years, a positive urine drug/alcohol test at Screening, or alcohol use\n             prior to the screening visit.\n\n          -  Regular use of any tobacco product, defined as smoke or smokeless product use\n             equivalent to >5 cigarettes/day for any consecutive week, within 3 months prior to\n             Day 1.\n\n        Other unspecified reasons that, in the opinion of the PI or Biogen Idec, make the subject\n        unsuitable for enrollment.\n\n        Other protocol-defined Inclusion/Exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "175", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01915901", 
            "org_study_id": "109HV110"
        }, 
        "intervention": [
            {
                "arm_group_label": "bismuth subsalicylate (Pepto-Bismol\u00ae) + DMF", 
                "description": "524 mg bismuth subsalicylate twice a day (BID)", 
                "intervention_name": "bismuth subsalicylate (Pepto-Bismol\u00ae)", 
                "intervention_type": "Drug", 
                "other_name": "Pepto-Bismol\u00ae"
            }, 
            {
                "arm_group_label": "Placebo + DMF", 
                "description": "placebo twice a day (BID)", 
                "intervention_name": "matching placebo (bismuth subsalicylate)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "bismuth subsalicylate (Pepto-Bismol\u00ae) + DMF", 
                    "Placebo + DMF"
                ], 
                "description": "dimethyl fumarate (DMF) twice a day (BID)", 
                "intervention_name": "dimethyl fumarate (DMF)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BG00012", 
                    "DMF", 
                    "TECFIDERA\u2122"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bismuth", 
                "Bismuth subsalicylate", 
                "Dimethyl fumarate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Daytona Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32117"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75247"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53704"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Double Blind, Placebo-Controlled Study of Pepto-Bismol\u00ae (Bismuth Subsalicylate) on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral TECFIDERA\u2122 (Dimethyl Fumarate) Delayed-Release Capsules Twice Daily", 
        "overall_official": {
            "affiliation": "Biogen Idec", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Time to first gastrointestinal-related event", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01915901"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The number of gastrointestinal-related events.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 8 weeks"
            }, 
            {
                "measure": "The duration of gastrointestinal-related events.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 8 weeks"
            }, 
            {
                "measure": "The severity of gastrointestinal-related events.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 8 weeks"
            }, 
            {
                "measure": "The percentage of subjects who discontinue dimethyl fumarate (DMF) due to gastrointestinal-related events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 8 weeks"
            }
        ], 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}